402948-34-9

Basic information

• Product Name: 3-Pyrrolidinamine, 1-(3-amino-4-nitrophenyl)-N,N-dimethyl-
• CAS NO: 402948-34-9
• Molecular Formula: C12H18N4O2
• Molecular Weight: 250.301
• Mol File: 402948-34-9.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 3-Pyrrolidinamine, 1-(3-amino-4-nitrophenyl)-N,N-dimethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyrrolidinamine, 1-(3-amino-4-nitrophenyl)-N,N-dimethyl-(402948-34-9)
• EPA Substance Registry System: 3-Pyrrolidinamine, 1-(3-amino-4-nitrophenyl)-N,N-dimethyl-(402948-34-9)

Safety Data

• Hazardous Substances Data: 402948-34-9(Hazardous Substances Data)

Upstream product

• 69478-75-7 dimethyl-pyrrolidin-3-yl-amine 

Downstream Products

• 402948-35-0 ethyl 2-{5-[3-(dimethylamino)pyrrolidinyl]benzimidazol-2-yl}acetate 
• 51-17-2 benzoimidazole 

Relevant articles and documents

Combination therapy with CHK1 inhibitors

Compounds of Structure I, and salts, tautomers, stereoisomers, and mixtures thereof may be used in methods of inhibiting checkpoint kinase 1 in subjects, in methods for inducing cell cycle progression, and in methods for increasing apoptosis in cells. Such compounds may be used to prepare pharmaceutical compositions and may be used in conjunction with DNA damaging agents.

BENZIMIDAZOLE QUINOLINONES AND USES THEREOF

Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes.

Heterocyclic compounds

Organic compounds having the structural formulas I, II, and III are provided where the variables have the values described herein and R1 and R2 in structure I join together to form a 5 to 7 membered substituted or unsubstituted ring including at least one O, N, or S atom, and Z is an O, S, NH or NR group in structures I and II. Pharmaceutical formulations include the organic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.